SYRE - CIK 0001636282
Spyre Therapeutics, Inc. trades as SYRE and has a market capitalization of $6.53 B, making it the #1199 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$155.20M. This page tracks Spyre Therapeutics, Inc. through 762 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -468.8% to -38238.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Major company event | 8-K | 2026-05-05 |
| Quarterly report | 10-Q | 2026-05-05 |
| Insider trade | 4 | 2026-05-01 |
| Insider sale notice | 144 | 2026-05-01 |
| Insider sale notice | 144 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
Event : Jefferies Global Healthcare Conference – New York
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The largest companies sharing Spyre Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $6.53 B as of 2026-06-10, ranking #1199 among US-listed companies.
Spyre Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025.
In its latest fiscal year Spyre Therapeutics, Inc. reported a net loss of $155.20M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.